American International Group Inc. Trims Stock Position in Boston Scientific Co. (NYSE:BSX)

American International Group Inc. reduced its stake in shares of Boston Scientific Co. (NYSE:BSXFree Report) by 2.8% in the 4th quarter, Holdings Channel reports. The fund owned 440,802 shares of the medical equipment provider’s stock after selling 12,801 shares during the period. American International Group Inc.’s holdings in Boston Scientific were worth $25,483,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of BSX. Bruce G. Allen Investments LLC acquired a new position in Boston Scientific in the 4th quarter worth about $28,000. Sachetta LLC purchased a new stake in Boston Scientific during the 4th quarter valued at about $32,000. Frazier Financial Advisors LLC purchased a new stake in shares of Boston Scientific in the fourth quarter valued at about $32,000. Jones Financial Companies Lllp increased its position in Boston Scientific by 53.0% during the fourth quarter. Jones Financial Companies Lllp now owns 557 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 193 shares during the last quarter. Finally, Venturi Wealth Management LLC raised its stake in Boston Scientific by 58.0% during the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 215 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Trading Down 0.3 %

NYSE:BSX traded down $0.20 on Friday, reaching $76.76. The stock had a trading volume of 3,540,518 shares, compared to its average volume of 5,008,300. The company has a market cap of $112.61 billion, a price-to-earnings ratio of 64.50, a P/E/G ratio of 2.64 and a beta of 0.81. Boston Scientific Co. has a 12-month low of $48.35 and a 12-month high of $77.64. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.66 and a quick ratio of 1.14. The firm’s fifty day moving average is $73.09 and its two-hundred day moving average is $66.09.

Boston Scientific (NYSE:BSXGet Free Report) last issued its quarterly earnings results on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.51 by $0.05. Boston Scientific had a return on equity of 16.39% and a net margin of 12.06%. The company had revenue of $3.86 billion for the quarter, compared to analyst estimates of $3.68 billion. Equities analysts expect that Boston Scientific Co. will post 2.32 EPS for the current fiscal year.

Analyst Ratings Changes

BSX has been the topic of a number of research analyst reports. TD Cowen lifted their target price on Boston Scientific from $65.00 to $77.00 and gave the company an “outperform” rating in a research report on Thursday, March 7th. Argus lifted their price target on Boston Scientific from $80.00 to $95.00 and gave the stock a “buy” rating in a report on Tuesday, May 28th. Mizuho upped their target price on shares of Boston Scientific from $85.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, May 15th. JPMorgan Chase & Co. raised their price target on Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Finally, StockNews.com lowered Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and a consensus target price of $76.70.

Get Our Latest Report on Boston Scientific

Insider Transactions at Boston Scientific

In related news, Director Edward J. Ludwig sold 9,818 shares of the business’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $73.29, for a total value of $719,561.22. Following the completion of the sale, the director now directly owns 41,374 shares in the company, valued at $3,032,300.46. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Edward J. Ludwig sold 9,818 shares of the business’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $73.29, for a total transaction of $719,561.22. Following the completion of the sale, the director now directly owns 41,374 shares of the company’s stock, valued at approximately $3,032,300.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Charles J. Dockendorff sold 3,946 shares of Boston Scientific stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $72.70, for a total value of $286,874.20. The disclosure for this sale can be found here. Insiders have sold a total of 81,627 shares of company stock worth $5,937,353 in the last three months. Company insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

(Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Featured Stories

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSXFree Report).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.